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LETTERS TO THE EDITOR
A Four-Year-Old Rabbit Cannot
Be Considered the Right Model
for Investigating Cardiac Senescence
Przyklenk et al. (1) have recently shown that cardioprotection with
ischemic preconditioning (PC) is preserved in the senescent heart.
The investigators found no differences in infarct size reduction by
PC among adult (4 to 6 months), middle aged (2 years) and old
(4 years) rabbits (1). Reduction of infarct size on “in vivo” rabbits
may be considered an appropriate experimental model to study
ischemic PC in animals. However, when considered in cardiac
aging, serious concerns arise about the experimental model in-
volved in their study. Indeed, animal models are used in aging
research to overcome the limitation of studying aging in humans
(e.g., the relatively long life span of humans). Because most aspects
of aging in rodents are similar to human aging despite their short
life span, rats and mice have been used extensively to study the
pathophysiology of aging (2).
In contrast, data on the senescent rabbit are not available
because of its relative long life span. In fact, the maximum life span
potential (MLSP) for rabbits is 13 years (3,4); thus, if we
optimistically consider MLSP for humans as 100 years, a 4-year-
old rabbit cannot be considered a good model of the aging heart.
A 4-year-old rabbit could be compared to a 30-year-old human
and obviously a 6-month-old rabbit to 4-year-old human.
Accordingly, morphologic markers of cardiovascular aging are
qualitatively but not quantitatively similar to that observed in
well-studied models of aging. Przyklenk et al. (1) showed that
mean myocyte cross-sectional area increased from 397 7 m2 in
adult to 445  11 m2 in middle aged (12%) and to 506 
10 m2 in old (27%) rabbits. In addition, the investigators also
claimed that myocardial collagen content increased from 6.2 
0.3% in adult versus 10.8 0.5% in old rabbit heart. In both cases,
these age-related modifications are significantly smaller than that
found by Anversa et al. (5), who demonstrated that myocyte cell
volume increases up to 60% from adult to senescent rat hearts
while collagen content increases from 7% in adult to 22% in
senescent rat hearts. The modifications showed by Przyklenk et al.
(1) are approximately half of those expected from a validated model
of the aging heart.
Conversely, reduction of ischemic PC mechanism has been well
established in a 24-month-old rat model (6–9) that proportionally
represents a human being of age 60 (rat MLSP  3.5 years) (2).
Moreover, Przyklenk et al. (1) also showed a slight reduction of
ischemic PC efficacy in two-year and three- to five-year versus
four- to six-month-old rabbit (15%). This is in agreement with
the concept that pathophysiologic modifications that occur during
aging are not “on–off ” and that ischemic PC might have a
progressive decline with aging. Infarct size progressively increases
in the preconditioned rat heart (9) from 15% in adult animals (3
months), to 25% in middle-aged (12 months) and to 40% in
old animals (20 months). Accordingly, as most of the age-related
pathophysiologic modifications were observed in the senescent rat
and human heart, ischemic PC was restored or preserved by
antiaging interventions such as exercise training (10,11). On the
basis of this evidence, ischemic PC efficacy should be significantly
reduced also in 7- to 8-year-old rabbits that probably represent the
24-month-rat and 60-year-old human homologues of cardiac
senescence.
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We thank Dr. Abete and colleagues for their interest in our work
(1) and for their query of whether the rabbit is the “right” model
to assess the efficacy of ischemic preconditioning (PC) in aging
animals.
The rabbit has not been extensively utilized in aging studies.
Indeed, there is even controversy as to the maximum life span of
the rabbit, with values of 7 years (2,3) versus 13 years (cited by
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